The use of adverse outcome pathways in the safety evaluation of food additives
Vinken, Mathieu ; Kramer, Nynke ; Allen, Timothy E.H. ; Hoffmans, Yvette ; Thatcher, Natalie ; Levorato, Sara ; Traussnig, Heinz ; Schulte, Stefan ; Boobis, Alan ; Thiel, Anette ; Rietjens, Ivonne M.C.M. - \ 2020
Archives of Toxicology 94 (2020). - ISSN 0340-5761
Adverse outcome pathway - Food additive - Safety evaluation
In the last decade, adverse outcome pathways have been introduced in the fields of toxicology and risk assessment of chemicals as pragmatic tools with broad application potential. While their use in the pharmaceutical and cosmetics sectors has been well documented, their application in the food area remains largely unexplored. In this respect, an expert group of the International Life Sciences Institute Europe has recently explored the use of adverse outcome pathways in the safety evaluation of food additives. A key activity was the organization of a workshop, gathering delegates from the regulatory, industrial and academic areas, to discuss the potentials and challenges related to the application of adverse outcome pathways in the safety assessment of food additives. The present paper describes the outcome of this workshop followed by a number of critical considerations and perspectives defined by the International Life Sciences Institute Europe expert group.
Characterizing the coverage of critical effects relevant in the safety evaluation of food additives by AOPs
Kramer, Nynke I. ; Hoffmans, Yvette ; Wu, Siyao ; Thiel, Anette ; Thatcher, Natalie ; Allen, Timothy E.H. ; Levorato, Sara ; Traussnig, Heinz ; Schulte, Stefan ; Boobis, Alan ; Rietjens, Ivonne M.C.M. ; Vinken, Mathieu - \ 2019
Archives of Toxicology 93 (2019)8. - ISSN 0340-5761 - p. 2115 - 2125.
3Rs - Acceptable daily intake - Adverse outcome pathway - Critical adverse effect - Food additives
There is considerable interest in adverse outcome pathways (AOPs) as a means of organizing biological and toxicological information to assist in data interpretation and method development. While several chemical sectors have shown considerable progress in applying this approach, this has not been the case in the food sector. In the present study, safety evaluation reports of food additives listed in Annex II of Regulation (EC) No 1333/2008 of the European Union were screened to qualitatively and quantitatively characterize toxicity induced in laboratory animals. The resulting database was used to identify the critical adverse effects used for risk assessment and to investigate whether food additives share common AOPs. Analysis of the database revealed that often such scrutiny of AOPs was not possible or necessary. For 69% of the food additives, the report did not document any adverse effects in studies based on which the safety evaluation was performed. For the remaining 31% of the 326 investigated food additives, critical adverse effects and related points of departure for establishing health-based guidance values could be identified. These mainly involved effects on the liver, kidney, cardiovascular system, lymphatic system, central nervous system and reproductive system. AOPs are available for many of these apical endpoints, albeit to different degrees of maturity. For other adverse outcomes pertinent to food additives, including gastrointestinal irritation and corrosion, AOPs are lacking. Efforts should focus on developing AOPs for these particular endpoints.
Novel approaches to derive points of departure for food chemical risk assessment
Levorato, Sara ; Rietjens, Ivonne M.C.M. ; Carmichael, Paul L. ; Hepburn, Paul A. - \ 2019
Current Opinion in Food Science 27 (2019). - ISSN 2214-7993 - p. 139 - 144.
Food chemical risk assessment characterizes the potential hazards and the associated health risks resulting from exposure of humans to chemicals present in food over a specified period. This requires the identification of points of departure, which are usually derived from apical toxicity endpoints in in vivo studies. However, a shift in the traditional paradigm in toxicity testing for risk assessment has started, and increasing attention is now being paid to the use of mechanistic-based and exposure-based approaches, including toxicogenomics and quantitative in vitro-to-in vivo extrapolation. This review outlines the most recent examples of application of these new approaches to derive points of departure in food chemical risk assessment, as well as the challenges limiting their full application and future directions.
Update of the Scientific Opinion on opium alkaloids in poppy seeds
Knutsen, Helle Katrine ; Alexander, Jan ; Barregård, Lars ; Bignami, Margherita ; Brüschweiler, Beat ; Ceccatelli, Sandra ; Cottrill, Bruce ; Dinovi, Michael ; Edler, Lutz ; Grasl‐Kraupp, Bettina ; Hogstrand, Christer ; Hoogenboom, Laurentius ; Nebbia, Carlo Stefano ; Oswald, Isabelle P. ; Petersen, Annette ; Rose, Martin ; Roudot, Alain-Claude ; Schwerdtle, Tanja ; Vollmer, Günter ; Wallace, Heather ; Benford, Diane ; Calò, Girolamo ; Dahan, Albert ; Dusemund, Birgit ; Mulder, Patrick ; Németh‐zámboriné, Éva ; Arcella, Davide ; Baert, Katleen ; Cascio, Claudia ; Levorato, Sara ; Schutte, Marijke ; Vleminckx, Christiane - \ 2018
EFSA Journal 16 (2018)5. - ISSN 1831-4732
Poppy seeds are obtained from the opium poppy (Papaver somniferum L.). They are used as food and to produce edible oil. The opium poppy plant contains narcotic alkaloids such as morphine and codeine. Poppy seeds do not contain the opium alkaloids, but can become contaminated with alkaloids as a result of pest damage and during harvesting. The European Commission asked EFSA to provide an update of the Scientific Opinion on opium alkaloids in poppy seeds. The assessment is based on data on morphine, codeine, thebaine, oripavine, noscapine and papaverine in poppy seed samples. The CONTAM Panel confirms the acute reference dose (ARfD) of 10 μg morphine/kg body weight (bw) and concluded that the concentration of codeine in the poppy seed samples should be taken into account by converting codeine to morphine equivalents, using a factor of 0.2. The ARfD is therefore a group ARfD for morphine and codeine, expressed in morphine equivalents. Mean and high levels of dietary exposure to morphine equivalents from poppy seeds considered to have high levels of opium alkaloids (i.e. poppy seeds from varieties primarily grown for pharmaceutical use) exceed the ARfD in most age groups. For poppy seeds considered to have relatively low concentrations of opium alkaloids (i.e. primarily varieties for food use), some exceedance of the ARfD is also seen at high levels of dietary exposure in most surveys. For noscapine and papaverine, the available data do not allow making a hazard characterisation. However, comparison of the dietary exposure to the recommended therapeutical doses does not suggest a health concern for these alkaloids. For thebaine and oripavine, no risk characterisation was done due to insufficient data. However, for thebaine, limited evidence indicates a higher acute lethality than for morphine and the estimated exposure could present a health risk.
Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed
Knutsen, Helle Katrine ; Alexander, Jan ; Barregård, Lars ; Bignami, Margherita ; Brüschweiler, Beat ; Ceccatelli, Sandra ; Cottrill, Bruce ; Dinovi, Michael ; Grasl‐Kraupp, Bettina ; Hogstrand, Christer ; Hoogenboom, Laurentius ; Nebbia, Carlo Stefano ; Oswald, Isabelle P. ; Petersen, Annette ; Rose, Martin ; Roudot, Alain-Claude ; Schwerdtle, Tanja ; Vleminckx, Christiane ; Vollmer, Günter ; Wallace, Heather ; Saeger, Sarah De; Eriksen, Gunnar Sundstøl ; Farmer, Peter ; Fremy, Jean-Marc ; Gong, Yun Yun ; Meyer, Karsten ; Parent‐Massin, Dominique ; Egmond, Hans van; Altieri, Andrea ; Colombo, Paolo ; Horváth, Zsuzsanna ; Levorato, Sara ; Edler, Lutz - \ 2018
EFSA Journal 16 (2018)8. - ISSN 1831-4732
4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the available data set, human acute and chronic health‐based guidance values (HBGV) were established based on data obtained in clinical trials of DAS as an anticancer agent (anguidine) after intravenous administration to cancer patients. The CONTAM Panel considered these data as informative for the hazard characterisation of DAS after oral exposure. The main adverse effects after acute and repeated exposure were emesis, with a no‐observed‐adverse‐effect level (NOAEL) of 32 μg DAS/kg body weight (bw), and haematotoxicity, with a NOAEL of 65 μg DAS/kg bw, respectively. An acute reference dose (ARfD) of 3.2 μg DAS/kg bw and a tolerable daily intake (TDI) of 0.65 μg DAS/kg bw were established. Based on over 15,000 occurrence data, the highest acute and chronic dietary exposures were estimated to be 0.8 and 0.49 μg DAS/kg bw per day, respectively, and were not of health concern for humans. The limited information for poultry, pigs and dogs indicated a low risk for these animals at the estimated DAS exposure levels under current feeding practices, with the possible exception of fattening chicken. Assuming similar or lower sensitivity than for poultry, the risk was considered overall low for other farm and companion animal species for which no toxicity data were available. In consideration of the similarities of several trichothecenes and the likelihood of co‐exposure via food and feed, it could be appropriate to perform a cumulative risk assessment for this group of substances.
Update of the risk assessment on 3‐monochloropropane diol and its fatty acid esters
Knutsen, Helle Katrine ; Alexander, Jan ; Barregård, Lars ; Bignami, Margherita ; Brüschweiler, Beat ; Ceccatelli, Sandra ; Cottrill, Bruce ; Dinovi, Michael ; Edler, Lutz ; Grasl‐Kraupp, Bettina ; Hoogenboom, Laurentius ; Nebbia, Carlo Stefano ; Oswald, Isabelle P. ; Petersen, Annette ; Rose, Martin ; Roudot, Alain-Claude ; Schwerdtle, Tanja ; Vleminckx, Christiane ; Vollmer, Günter ; Wallace, Heather ; Lampen, Alfonso ; Morris, Ian ; Piersma, Aldert ; Schrenk, Dieter ; Binaglia, Marco ; Levorato, Sara ; Hogstrand, Christer - \ 2018
EFSA Journal 16 (2018)1. - ISSN 1831-4732
The CONTAM Panel updated the assessment of the risks for human health related to the presence of 3‐monochloropropane diol (3‐MCPD) and its fatty acid esters in food published in 2016 in view of the scientific divergence identified in the establishment of the tolerable daily intake (TDI) in the Joint FAO/WHO Expert Committee on Food Additives and Contaminants (FAO/WHO) report published in 2017. In this update, dose–response analysis was performed following the recent EFSA Scientific Committee guidance on the use of benchmark dose (BMD) approach in risk assessment, and a review of available data on developmental and reproduction toxicity was included. The outcome of this review indicates that in rats short‐term exposure to 3‐MCPD above 1 mg/kg body weight (bw) per day can induce reduced sperm motility associated with reduced male fecundity. Decreased sperm count and histopathological changes in the testis and epididymis were observed following longer treatment periods at higher doses. Regarding increased incidence kidney tubular hyperplasia, BMD analysis using model averaging resulted in a BMDL10 of 0.20 mg/kg bw per day in male rats, which was selected as the new Reference Point (RP) for renal effects. For the effects on male fertility, decreased sperm motility was selected as the most sensitive relevant endpoint and a BMDL05 of 0.44 mg/kg bw per day was calculated. The RP for renal effects was considered to derive an updated group TDI of 2 μg/kg bw per day for 3‐MCPD and its fatty acid esters and was considered protective also for effects on male fertility. The established TDI of 2 μg/kg bw per day is not exceeded in the adult population. A slight exceedance of the TDI was observed in the high consumers of the younger age groups and in particular for the scenarios on infants receiving formula only.
Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food
Knutsen, Helle Katrine ; Alexander, Jan ; Barregård, Lars ; Bignami, Margherita ; Brüschweiler, Beat ; Ceccatelli, Sandra ; Cottrill, Bruce ; Dinovi, Michael ; Edler, Lutz ; Grasl‐Kraupp, Bettina ; Hogstrand, Christer ; Hoogenboom, Laurentius ; Nebbia, Carlo Stefano ; Oswald, Isabelle P. ; Petersen, Annette ; Rose, Martin ; Roudot, Alain-Claude ; Vleminckx, Christiane ; Vollmer, Günter ; Wallace, Heather ; Bodin, Laurent ; Cravedi, Jean-Pierre ; Halldorsson, Thorhallur Ingi ; Haug, Line Småstuen ; Johansson, Niklas ; Loveren, Henk van; Gergelova, Petra ; Mackay, Karen ; Levorato, Sara ; Manen, Mathijs van; Schwerdtle, Tanja - \ 2018
EFSA Journal 16 (2018)12. - ISSN 1831-4732
The European Commission asked EFSA for a scientific evaluation on the risks to human health related to the presence of perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in food. Regarding PFOS and PFOA occurrence, the final data set available for dietary exposure assessment contained a total of 20,019 analytical results (PFOS n = 10,191 and PFOA n = 9,828). There were large differences between upper and lower bound exposure due to analytical methods with insufficient sensitivity. The CONTAM Panel considered the lower bound estimates to be closer to true exposure levels. Important contributors to the lower bound mean chronic exposure were ‘Fish and other seafood’, ‘Meat and meat products’ and ‘Eggs and egg products’, for PFOS, and ‘Milk and dairy products’, ‘Drinking water’ and ‘Fish and other seafood’ for PFOA. PFOS and PFOA are readily absorbed in the gastrointestinal tract, excreted in urine and faeces, and do not undergo metabolism. Estimated human half‐lives for PFOS and PFOA are about 5 years and 2–4 years, respectively. The derivation of a health‐based guidance value was based on human epidemiological studies. For PFOS, the increase in serum total cholesterol in adults, and the decrease in antibody response at vaccination in children were identified as the critical effects. For PFOA, the increase in serum total cholesterol was the critical effect. Also reduced birth weight (for both compounds) and increased prevalence of high serum levels of the liver enzyme alanine aminotransferase (ALT) (for PFOA) were considered. After benchmark modelling of serum levels of PFOS and PFOA, and estimating the corresponding daily intakes, the CONTAM Panel established a tolerable weekly intake (TWI) of 13 ng/kg body weight (bw) per week for PFOS and 6 ng/kg bw per week for PFOA. For both compounds, exposure of a considerable proportion of the population exceeds the proposed TWIs.